Cytomegalovirus Viremia, Pneumonitis, and Tocilizumab Therapy

van Duin, David; Miranda, Cyndee; Husni, Elaine

doi:10.3201/eid1706.101057

Back to Previous Page

Cytomegalovirus Viremia, Pneumonitis, and Tocilizumab Therapy

Apr 2011

By van Duin, David ; Miranda, Cyndee ; Husni, Elaine ;

http://dx.doi.org/10.3201/eid1706.101057

Source: Emerg Infect Dis. 17(4):754-756.

[PDF-126.76 KB]

English

Details Supporting Files You May Also Like

Details:

Alternative Title:

Emerg Infect Dis

Publisher's site:

http://dx.doi.org/10.3201/eid1706.101057

Personal Author:

van Duin, David; Miranda, Cyndee; Husni, Elaine;

Subject:

[+]

Source:

Emerg Infect Dis. 17(4):754-756.;

Document Type:

Letter;

Collection(s):

Emerging Infectious Diseases

Main Document Checksum:

[+]

File Type:

	10-1057-F.gif	gif
	10-1057-F.jpg	jpeg
	10-1057_finalL.nxml	txt
	license.txt	txt

More +

You May Also Like

Invasive Cryptococcosis and Adalimumab Treatment

Cite

Horcajada, Juan P. ; Peña, Jose L. ; ...

Jun 2007 | Emerg Infect Dis. 13(6):953-955.

No Description

[PDF - 149.71 KB]

High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine

Cite

McNamara, Lucy A. ; Topaz, Nadav ; ...

Jul 14 2017 | MMWR Morb Mortal Wkly Rep. 66(27):734-737.

Use of eculizumab (Soliris, Alexion Pharmaceuticals), a terminal complement inhibitor, is associated with a 1,000-fold to 2,000-fold increased inciden...

[PDF - 234.04 KB]

Checkout today's featured content at stacks.cdc.gov

Cytomegalovirus Viremia, Pneumonitis, and Tocilizumab Therapy

Cytomegalovirus Viremia, Pneumonitis, and Tocilizumab Therapy

Details:

You May Also Like

Have Questions?

CDC INFORMATION

CONNECT WITH CDC